Lost In Reimbursement? Innovative Drugs Encounter Lengthy Delays In China – IMS Study
This article was originally published in PharmAsia News
Executive Summary
A market access study conducted by IMS and RDPAC sheds lights on regulatory and reimbursement challenges facing MNCs in China.